Treatment of venous thromboembolism in patients with cancer: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)Tiziano Barbui, Professor, Fondazione Ospedale Maggiore, Bergamo, ItalyDavide Tassinari, Supportive and Palliative Care Unit, Department of Oncology, City Hospital, Rimini, Italy.

Thrombosis Research

Volumn 124, Issue 5, 2009, Pages

  Imberti, Davide ^a   Di Nisio, Marcello ^b   Donati, Maria Benedetta ^c   Falanga, Anna ^d   Ghirarduzzi, Angelo ^e   Guarneri, Daniele ^f   Piovella, Franco ^g   Santoro, Rita Carlotta ^h   Baldini, Edoardo ^a   Zampogna, Stefania ⁱ  

^a Piacenza Hospital   (Italy)

^b 'SSma Annunziata' Hospital   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d Haematology Division   (Italy)

^e S MARIA NUOVA HOSPITAL   (Italy)

^f Accident and Emergency Medicine Department   (Italy)

^g FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^h Oncohaematology Department   (Italy)

ⁱ PUGLIESE CIACCIO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ANTIVITAMIN K; DALTEPARIN; ENOXAPARIN; FLUOROURACIL; FONDAPARINUX; HEPARIN; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; RETEPLASE; TINZAPARIN; WARFARIN; XIMELAGATRAN;

ABSENCE OF SIDE EFFECTS; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; BLOOD FILTER; CACHEXIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CATHETER THROMBOSIS; CAVA VEIN; CLINICAL PRACTICE; CLINICAL TRIAL; COMPRESSION GARMENT; CONSENSUS DEVELOPMENT; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DRUG FATALITY; DRUG WITHDRAWAL; ECONOMIC ASPECT; HEPARIN INDUCED THROMBOCYTOPENIA; HOME CARE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LEUKEMIA; LUNG EMBOLISM; LYMPHOMA; MEDICAL SOCIETY; MYELOMA; MYELOPROLIFERATIVE DISORDER; NEOPLASM; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE; REPEATED DRUG DOSE; SINGLE DRUG DOSE; SURGICAL THROMBECTOMY; THROMBOCYTOPENIA; THROMBOSIS PREVENTION; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; VOMITING;

HUMANS; ITALY; NEOPLASMS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 70349869341     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2009.08.006     Document Type: Article

References (102)

1. Heit J.A., Mohr D.N., Silverstein M.D., Petterson T.M., O 'Fallon W.M., and Melton L.J. Predictor of recurrence after deep vein thrombosis and pulmonary embolism. A population-based cohort study. Arch Intern Med 160 (2000) 761-768
2. Levitan N., Dowlati A., Remick S.C., Tahsildar H.I., Sivinski L.D., Beyth R., et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine 78 (1999) 285-291
3. Prandoni P. How I treat venous thromboembolism in patients with cancer. Blood 106 (2005) 4027-4033
4. Prandoni P., Falanga A., and Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 6 (2005) 401-410
5. Falanga A., and Zacharski L. Deep vein thrombosis in cancer: the scale of the problem and approaches to management. Ann Oncol 16 (2005) 696-701
6. Noble S.I., Shelley M.D., Coles B., Williams S.M., Wilcock A., and Johnson M.J. Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis. Lancet Oncol 9 (2008) 577-584
7. Imberti D., Agnelli G., Ageno W., Moia M., Palareti G., Pistelli R., et al. Clinical characteristics and management of cancer-associated acute venous thromboembolism: Findings from the MASTER Registry. Haematologica 93 2 (2008) 273-278
8. Lee A.Y. Management of thrombosis in cancer: primary prevention and secondary prophylaxis. Br J Haematol 128 (2005) 291-302
9. Lorio A., Ageno W., Cosmi B., Imberti D., Lussana F., Siragusa S., Tormene D., Tosetto A., and Cattaneo M. Objectives and methodology: Guidelines of the Italian Society for Haemostasis and Thrombosis. Thromb Res 124 (2009) e1-e5
10. Scottish Intercollegiate Guidelines Network, SIGN 50: A guideline developers' handbook, SIGN Publication No. 50. February 2001, last updated May 2004. Available from: http://www.sign.ac.uk.
11. Koopman M.M., Prandoni P., Piovella F., Ockelford P.A., Brandjes D.P., Gallus A.S., et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 334 (1996) 682-687
12. Levine M., Gent M., Hirsh J., LeClerc J., Anderson D., Weitz J., et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. N Engl J Med 334 (1996) 677-681
13. Merli G., Spiro T.E., Olsson C.G., Abildgaard U., Davidson B.L., Eldor A., et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of thromboembolic disease. Ann Intern Med 134 (2001) 191-202
14. Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 337 (1997) 657-662
15. Gould M.K., Dembitzer A.D., Doyle R.L., Hastie T.J., and Garber A.M. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep vein thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 130 (1999) 800-809
16. Dolovich L.R., Ginsberg J., Douketis J.D., Holbroch A.M., and Cheah J. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 160 (2000) 181-188
17. Dongen C.J.J., Van Der Belt A.G.M., and Prins M.H. Fixed dose subcutaneous low-molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. The Cochrane Database of Sistematic Reviews (2004) Issue 4
18. Akl E.A., Rohilla S., Barba M., Sperati F., Terrenato I., Muti P., et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 1 (2008) CD006649
19. Kearon C., Kahn S.R., Agnelli G., Goldhaber S., Raskob G.E., and Comerota A.J. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133 SUPPL. 6 (2008) 454 S-545S
20. Lyman G.H., Khorana A.A., Falanga A., Clarke-Pearson D., Flowers C., Jahanzeb M., Kakkar A., Kuderer N.M., Levine M.N., Liebman H., et al. American Society of Clinical Oncology Guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25 (2007) 5490-5505
21. Hyers T.M., and Spyropoulos A.C. Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarin. J Thromb Trombolysis 24 (2007) 225-232
22. Palareti G., Legnani C., Lee A., Manotti A., Hirsh J., D 'Angelo A., et al. A comparison of the safety and efficacy of oral anticoagulant for the treatment of venous thromboembolic disease in patient with or without malignancy. Thromb Haemost 84 (2000) 805-810
23. Hutten B.A., Prins M.H., Gent M., Ginsberg J., Tijssen J.G., and Buller H.R. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 18 (2000) 3078-3083
24. Prandoni P., Lensing A.W., Piccioli A., Bernardi E., Simioni P., Girolami B., et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100 (2002) 3484-3488
25. Lee A.Y., Levine M.N., Baker R.I., Bowden C., Kakkar A.K., and Prins M.H. Low-molecular-weight heparin versus coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349 (2003) 146-153
26. Meyer G., Marjanovic Z., Valcke J., Lorcerie B., Gruel Y., and Solal-Celigny P. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 162 (2002) 1729-1735
27. Hull R.D., Pineo G.F., Brant R.F., Mah A.F., Burke N., Dear R., et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 119 (2006) 1062-1072
28. Akl E., Barba M., Rohilla S., Terrenato I., Sperati F., Muti P., et al. Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2 (2008) :CD006650
29. Prandoni P., Lensing A.W.A., and Cogo A. The long term clinical course of acute deep vein thrombosis. Ann Intern Med 125 (1996) 1-7
30. Noble S.I., and Finlay I.G. Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study. Palliat Med 19 (2005) 197-201
31. Noble S.I.R., Hood K., and Finlay I.G. The use of long-term low-molecular weight heparin for the treatment of venous thromboembolism in palliative care patients with advanced cancer: A case series of sixty two patients. Palliat Med 21 6 (2007) 473-476
32. Luk C., Wells P.S., Anderson D., and Kovacs M.J. Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy. Am J Med 111 (2001) 270-273
33. Buller H.R., Davidson B.L., and Decousus H. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep vein thrombosis: a randomized trial. Ann Intern Med 104 (2004) 867-873
34. The MATISSE Investigator. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 349 (2003) 1695-1702
35. Persist Investigators. A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis: a phase II evaluation. J Thromb Haemost 2 (2004) 47-53
36. Van Gogh Investigators, Buller H.R., Cohen A.T., Davidson B., Decousus H., Gallus A.S., et al. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 357 (2007) 1094-1104
37. Watson L.I., and Armon M.P. Thrombolysis for acute deep vein thrombosis (review). Cochrane Database Syst Rev 4 (2004) CD002783 .N° CD002783.pub2
38. Torbicki A., Perrier A., Konstantinides S., Agnelli G., Galie N., Pruszczyk P., Bengel F., Brady A.J.B., Ferreira D., Janssens U., et al. Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 29 (2008) 2276-2315
39. Kasirajan K., Gray B., and Ouriel K. Percutaneous Angiojet Thrombectomy in the management of extensive deep venous trombosis. J Vasc Interv Radiol 12 (2001) 179-185
40. Lucon A.M., Machado M.C., and Pereira M.A. Surgery for adrenal tumours with thrombus in the supra-diaphragmatic infra-atrial inferior vena cava, with no cardiopulmonary bypass. BJU Int 94 (2004) 70-73
41. Jibiki M., Iwai T., and Inoue Y. Surgical strategy for treating renal cell carcinoma with thrombus extending into the inferior vena cava. J Vasc Surg 39 (2004) 829-835
42. Oikawa T., Shimazui T., and Johraku A. Intraoperative transesophageal echocardiography for inferior vena caval tumor thrombus in renal cell carcinoma. Int J Urol 11 (2004) 189-192
43. Bissada N.K., Yakout H.H., and Babanouri A. Long-term experience with management of renal cell carcinoma involving the inferior vena cava. Urology 61 (2003) 89-92
44. Kaplan S., Ekici S., and Dogan R. Surgical management of renal cell carcinoma with inferior vena cava tumor thrombus. Am J Surg 183 (2002) 292-299
45. Li M.K., Yip S.K., and Cheng W.S. Inferior vena cava thrombectomy for renal cell carcinoma with thrombus. Ann Acad Med Singap 28 (1999) 508-511
46. Terakawa T., Miyake H., Takenaka A., Hara I., and Fujisawa M. Clinical outcome of surgical management for patients with renal cell carcinoma involving the inferior vena cava. Int J Urol 14 (2007) 781-784
47. Wang G.J., Carpenter J.P., Fairman R.M., Jackson B.M., Malkowicz B., Van Arsdalen K.N., et al. Single-center experience of caval thrombectomy in patients with renal cell carcinoma with tumor thrombus extension into the inferior vena cava. Vasc Endovasc Surg 42 (2008) 335-340
48. Zini L., Koussa M., Haulon S., Decoene C., Fantoni J.C., Biserte J., et al. Results of endoluminal occlusion of the inferior vena cava during radical nephrectomy and thrombectomy. Eur Urol 54 (2008) 778-784
49. Sakuragi T., Sakao Y., Furukawa K., Rikitake K., Ohtsubo S., Okazaki Y., et al. Successful management of acute pulmonary embolism after surgery for lung cancer. Eur J Cardiothorac Surg 24 (2003) 580-587
50. Kalweit G., Huwer H., Volkmer I., Petzold T., and Gams E. Pulmonary embolism: a frequent cause of acute fatality after lung resection. Eur J Cardiothorac Surg 10 (1996) 242-246
51. Decousus H., Leizorovicz A., Parent F., Page Y., Tardy B., Girard P., et al. A clinical trial of vena cava filters in the prevention of pulmonary embolism in patients withproximal deep-vein thrombosis. N Engl J Med 338 (1998) 409-415
52. The PREPIC Study Group. Eight-year Follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism. Circulation 112 (2005) 416-422
53. Nieto J.A., De Tuesta A.D., Marchena P.J., and Monreal M. Clinical outcome of patients with venous thromboembolism and recent major bleedings: findings from a prospective registry (RIETE). J Thromb Haemost 3 (2005) 703-709
54. Gerber D.E., Grossman S.A., and Streiff M.B. Management of venous thromboembolism in patients with primary and metastatic brain tumors. J Clin Oncol 24 (2006) 1310-1318
55. Wallace M.J., Jean J.L., Gupta S., Eapen G.A., Johnson M.M., Ahrar K., et al. Use of inferior vena cava filters and survival in patients with malignancy. Cancer 101 (2004) 1902-1907
56. Ihnat D.M., Mills J.L., Hughes J.D., Gentile A.T., Berman S.S., and Westerband A. Treatment of patients with venous thromboembolism and malignant disease: should vena cava filter placement be routine?. J Vasc Surg 28 (1998) 800-807
57. Ghanim A.J., Daskalakis C., Eschelman D.J., and Kraft W.K. A five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants. J Thromb Trombolysis 24 3 (2007) 247-254
58. Schmidt F., Faul C., Dichgans J., and Weller M. Low molecular weight heparin for deep vein thrombosis in glioma patients. J Neurol 249 (2002) 1409-1412
59. Knovich M.A., and Lesser G.J. The management of thromboembolic disease in patients with central nervous system malignancies. Curr Treat Options Oncol 5 (2004) 511-517
60. Altschuler E., Moosa H., Selker G.R., and Vertosick F.T. The risk and efficacy of antioagulant therapy in the treatment of thromboembolic complications in patients with primary malignant brain tumors. Neurosurgery 27 (1990) 74-77
61. Ruff R.L., and Posner J.B. Incidence and treatment of peripheral venous thrombosis in patients with glioma. Ann Neurol 13 (1983) 334-336
62. Ginberg J.S., Hirsch J., and Julian J. Prevention and treatment of postphlebitic syndrome: results of a 3-part study. Arch Intern Med 161 161 (2001) 2105-2109
63. Brandjes D.P., Buller H.R., Heijboer H., Huisman M.V., de Rijk M., Jagt H., et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 349 (1997) 759-762
64. Prandoni P., Lensing A.W., Prins M.H., Frulla M., Marchiori A., Bernardi E., et al. Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med 141 (2004) 249-256
65. Ageno W., Steidl L., Marchesi C., Dentali F., Mera V., Squizzato A., et al. Selecting patients for home treatment of deep vein thrombosis: the problem of cancer. Haematologica 87 (2002) 286-291
66. Ageno W., Grimwood R., Limbiati S., Dentali F., Steidl L., and Wells P.S. Home-treatment of deep vein thrombosis in patients with cancer. Haematologica 90 (2005) 220-224
67. De Stefano V., Sorà F., Rossi E., Chiusolo P., Laurenti L., Fianchi L., et al. The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost 3 (2005) 1985-1992
68. Ziegler S., Sperr W.R., Knobl P., Lehr S., Weltermann A., Jager U., et al. Symptomatic venous thromboembolism in acute leukaemia. Incidence, risk factors, and impact on prognosis. Thromb Res 115 (2005) 59-64
69. Mohren M., Markmann I., and Jentsch-Ullrich K. Patient with malignant lymphoma: a single center analysis. Br J Cancer 92 (2005) 1349-1352
70. Blom J.W., Vanderschoot J.P.M., Oostindier M.J., Osanto S., Van Der Meer J.M., and Rosendaal F.R. Incidence of venous thromboembolism in a large cohort of 66329 cancer patients: results of a record linkage study. J Thromb Haemost 4 (2006) 529-535
71. Rickles F.R., Falanga A., Montesinos P., Sanz M.A., Brenner B., and Barbui T. Bleeding and thrombosis in acute leukemia: What does the future of therapy look like?. Thromb Res 120 SUPPL.2 (2007) S99-S106
72. Payne J.H., and Vora A.J. Thrombosis and acute lymphoblastic leukaemia. Br J Haematol 138 4 (2007) 430-445
73. Athale U.H., Nagel K., Khan A.A., and Chan A.K.C. Thromboembolism in children with lymphoma. Thromb Res 122 4 (2008) 459-465
74. Khorana A.A., Francio C.W., Culakova E., Fisher R.I., Kuderer N.M., and Lyman G.H. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 24 (2006) 484-490
75. Imberti D., Vallisa D., Anselmi E., Moroni C.F., Bertè R., Lazzaro A., et al. Safety and efficacy of enoxaparin treatment in venous thromboembolic disease during acute leukemia. Tumori 90 (2004) 390-393
76. Herishanu Y., Misgav M., Kirgner I., Ben-Tal O., Eldor A., and Naparstek E. Enoxaparin can be used safely in patients with severe thrombocytopenia due to intensive chemotherapy regimens. Leuk Lymphoma 45 (2004) 1407-1411
77. Elliott M.A., and Tefferi A. Thrombosis and haemorrhage in polycythemia vera and essential thrombocythaemia. Br J Haematol 128 (2004) 275-290
78. De Stefano V., Za T., Rossi E., Vannucchi A.M., Ruggeri M., Elli E., Mico C., Tieghi A., Cacciola R.R., Santoro C., et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: Incidence, risk factors, and effect of treatments. Haematologica 93 (2008) 372-380
79. Landolfi R., Di Gennaro L., and Falanga A. Thrombosis in myeloproliferative disorders: Pathogenetic facts and speculation. Leukemia 22 11 (2008) 2020-2028
80. Mc Mullin M.F., Bareford D., Campbell P., Green A.R., Harrison C., Hunt B., et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol 130 (2005) 174-195
81. Barbui T., Barosi G., Grossi A., Gugliotta L., Liberato L.N., Marchetti M., et al. Evidence- and consensus-based practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology. Haematologica 89 (2004) 215-232
82. Monreal M., and Davant E. Thrombotic complications of central catheters in cancer patients. Acta Haematol 106 (2001) 69-72
83. Verso M., and Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 21 (2003) 3665-3675
84. Sanchez J.D.A., Battle J.F., and Feijoo J.B. Catheter-related thrombosis: A critical review. Supportive Cancer Ther 4 3 (2007) 145-151
85. Flinterman L.E., Van Der Meer F.J.M., Rosendaal F.R., and Doggen C.J.M. Current perspective of venous thrombosis in the upper extremity. J Thromb Haemost 6 8 (2008) 1262-1266
86. Bernardi E., Piccioli A., Marchiori A., Girolami B., and Prandoni P. Upper extremity deep vein thrombosis: risk factors, diagnosis, and management. Semin Vasc Med 1 (2001) 105-110
87. Prandoni P., Polistena P., Bernardi E., Cogo A., Casara D., Verlato F., et al. Upper extremity deep vein thrombosis. Risk factors, diagnosis, and complications. Arch Intern Med 157 (1997) 57-62
88. Monreal M., Lafoz E., Ruiz J., Valls R., and Alastrue A. Upper extremity deep vein thrombosis and pulmonary embolism. A prospective study. Chest 9 (1991) 280-283
89. Monreal M., Raventos A., Lerma R., Ruiz J., Lafoz E., Alastrue A., et al. Pulmonary embolism in patients with upper extremity DVT associated to venous central lines. A prospective study. Thromb Haemost 72 (1994) 548-550
90. Karabay O., Yetkin U., and Onol H. Upper extremities deep vein thrombosis: clinical and treatment characteristics. Int Med Res 32 (2004) 429-435
91. Savage K.J., Wells P.S., Schulz V., Goudie D., Morrow B., and Cruickshank M. Outpatient use of low molecular weight heparin (Dalteparin) for the treatment of deep vein thrombosis of the upper extremities. Thromb Haemost 82 (1999) 1008-1010
92. Bona R.D. Thrombotic complications of central venous catheters in cancer patients. Semin Thromb Haemost 25 (1999) 147-155
93. Liu C.Y., Jain V., Shields A.F., and Heilbrun L.K. Efficacy and safety of reteplase for central venous catheter occlusion in patients with cancer. J Vasc Interv Radiol 15 (2004) 39-44
94. Chesler L., and Feusner J.H. Use of tissue plasminogen activator (rt-PA) in young children with cancer and dysfunctional central venous catheter. J Pediatr Hematol Oncol 24 (2002) 653-656
95. Haire W.D., Atkinson J.B., Stephens L.C., and Kotulak G.D. Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: a double-blinded, randomized trial. Thromb Haemost 72 (1994) 543-547
96. Fraschini G., Jadeja J., Lawson M., Holmes F.A., Carrasco H.C., and Wallace S. Local infusion of urokinase for the lysis of thrombosis associated with permanent central venous catheter in cancer patients. J Clin Oncol 5 (1987) 672-678
97. Schindler J., Bona R.D., Chen H.H., Feingold J.M., Edwards R.L., Tutschka P.J., et al. Regional thrombolysis with urokinase for central venous catheter-related thrombosis in patients undergoing high-dose chemotherapy with autologous blood stem cell rescue. Clin Appl Thromb Hemost 5 (1999) 25-29
98. Frank D.A., Meuse J., Hirsch D., Ibrahim J.G., and Van Den Abbeele A.D. The treatment and outcome of cancer patients with thromboses on central venous catheters. J Thromb Thrombolysis 10 (2000) 271-275
99. Kovacs M.J., Kahn S.R., Rodger M., Anderson D.R., Andreou R., Mangel J.E., et al. A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study). J Thromb Haemost 5 8 (2007) 1650-1653
100. Otten H.M., Mathijssen J., and Ten Cate H. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med 164 (2004) 190-194
101. Bona R.D., Sivjce K.Y., Hyckey A.D., Wallace D.H., and Waics S.B. The efficacy and safety of oral anticoagulantion in patients with cancer. Thromb Haemost 74 (1995) 1055-1058
102. Brown R.C. An adverse interaction between warfarin and 5-fluorouracil: a case report and review of the literature. Chemotherapy 45 (1999) 392-395